NEUP · Neuphoria Therapeutics Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '25 | Q1 '25 | Q3 '25 | Q2 '24 | Q2 '23 | Q2 '22 |
|---|---|---|---|---|---|---|---|
| Revenue | - | $662.7K | - | $15.00M | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| R&D | - | $697.7K | $3.79M | $1.20M | - | - | - |
| SG&A | $1.69M | $2.13M | $1.87M | $1.20M | - | - | - |
| Total Operating Expenses | $1.21M | $4.06M | $5.65M | $2.39M | - | - | - |
| D&A | - | - | $165.8K | - | - | - | - |
| Operating Income | ($1.21M) | ($4.06M) | ($5.65M) | ($2.39M) | - | - | - |
| Interest Expense | - | - | - | - | - | - | - |
| Income Tax | ($34.8K) | ($34.8K) | ($34.8K) | $16.4K | - | - | - |
| Net Income | ($505.1K) | $1.86M | ($9.91M) | ($2.78M) | - | - | - |
| EPS - Basic | ($0.09) | $0.41 | ($4.41) | ($2.83) | - | - | - |
| EPS - Diluted | ($0.09) | ($0.77) | ($4.41) | ($2.83) | - | - | - |
Balance Sheet
| Line item | Q3 '26 | Q2 '25 | Q1 '25 | Q3 '25 | Q2 '24 | Q2 '23 | Q2 '22 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.44M | $22.17M | $13.65M | $17.04M | $12.61M | $12.10M | $23.21M |
| Accounts Receivable | $1.61M | $1.11M | $1.8K | $24.6K | $126.9K | $426.1K | - |
| Inventory | - | - | - | - | - | - | - |
| Accounts Payable | $627.2K | $520.7K | $1.37M | $745.3K | $2.24M | $1.44M | - |
| Current Assets | $21.66M | $23.39M | $13.95M | $17.09M | $13.19M | $13.33M | - |
| Total Assets | $34.81M | $36.60M | $27.34M | $30.71M | $27.65M | $28.56M | - |
| Current Liabilities | $1.51M | $2.59M | $5.12M | $1.55M | $3.83M | $2.74M | - |
| Long-term Debt | - | - | - | - | - | - | - |
| Total Liabilities | $5.39M | $6.90M | $14.83M | $4.72M | $10.16M | $6.55M | - |
| Stockholders' Equity | $29.42M | $29.70M | $12.51M | $17.95M | $17.49M | $22.01M | $39.23M |
| Retained Earnings | ($186.89M) | ($186.39M) | ($188.25M) | ($169.46M) | ($177.98M) | ($162.48M) | - |
Cash Flow
| Line item | Q3 '26 | Q2 '25 | Q1 '25 | Q3 '25 | Q2 '24 | Q2 '23 | Q2 '22 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($3.79M) | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $3.25M | - | - | - | - |
| CapEx | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '25 | Q1 '25 | Q3 '25 | Q2 '24 | Q2 '23 | Q2 '22 |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross margin | - | - | - | - | - | - | - |
| Operating margin | - | -612.8% | - | -16.0% | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - |
| Net margin | - | 281.3% | - | -18.5% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - |
| R&D / Revenue | - | 105.3% | - | 8.0% | - | - | - |
| SG&A / Revenue | - | 320.9% | - | 8.0% | - | - | - |
| Effective tax rate | - | -1.9% | - | - | - | - | - |
| Return on assets | -1.5% | 5.1% | -36.2% | -9.0% | - | - | - |
| Return on equity | -1.7% | 6.3% | -79.2% | -15.5% | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - |
| Liquidity | |||||||
| Current ratio | 14.31 | 9.04 | 2.72 | 11.01 | 3.45 | 4.87 | - |
| Quick ratio | 14.31 | 9.04 | 2.72 | 11.01 | 3.45 | 4.87 | - |
| Cash ratio | 12.85 | 8.57 | 2.66 | 10.98 | 3.29 | 4.42 | - |
| Leverage | |||||||
| Debt / Equity | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - |
| Equity multiplier | 1.18 | 1.23 | 2.19 | 1.71 | 1.58 | 1.30 | - |
| Liabilities / Assets | 0.15 | 0.19 | 0.54 | 0.15 | 0.37 | 0.23 | - |
| Efficiency | |||||||
| Asset turnover | - | 0.02 | - | 0.49 | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - |
| Days sales outstanding | - | 611d | - | 1d | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - |
| Valuation | |||||||
| P / E | - | - | - | - | - | - | - |
| P / B | 0.7x | 0.6x | 2.1x | 0.3x | - | - | - |
| P / S | - | 26.6x | - | 0.4x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| Growth | |||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 49.4% | - | - | - | - | - | - |
| Net income growth (YoY) | 81.8% | - | - | - | - | - | - |
| EPS growth (YoY) | 96.8% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - |
| Book value growth (YoY) | 64.0% | 69.8% | - | - | -20.5% | -43.9% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Neuphoria Therapeutics Inc. against the 5 most active filers in the same SIC group.